MA47408A - CANCER TREATMENT - Google Patents
CANCER TREATMENTInfo
- Publication number
- MA47408A MA47408A MA047408A MA47408A MA47408A MA 47408 A MA47408 A MA 47408A MA 047408 A MA047408 A MA 047408A MA 47408 A MA47408 A MA 47408A MA 47408 A MA47408 A MA 47408A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer treatment
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17209098 | 2017-12-20 | ||
| PCT/EP2018/052694 WO2018141921A1 (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA47408A true MA47408A (en) | 2019-12-11 |
| MA47408B1 MA47408B1 (en) | 2023-08-31 |
Family
ID=60702421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA47408A MA47408B1 (en) | 2017-12-20 | 2018-02-02 | CANCER TREATMENT |
Country Status (5)
| Country | Link |
|---|---|
| EA (1) | EA201991818A1 (en) |
| MA (1) | MA47408B1 (en) |
| PT (1) | PT3576740T (en) |
| TW (1) | TWI798199B (en) |
| WO (1) | WO2018141921A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12133851B2 (en) * | 2018-09-21 | 2024-11-05 | Janssen Pharmaceutica Nv | Treatment of cholangiocarcinoma |
| US12180207B2 (en) | 2018-12-19 | 2024-12-31 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases |
| US12351571B2 (en) | 2018-12-19 | 2025-07-08 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases |
| CA3126959A1 (en) * | 2019-02-12 | 2020-08-20 | Janssen Pharmaceutica Nv | Cancer treatment |
| CA3133348A1 (en) * | 2019-03-15 | 2020-09-24 | Poly-Med, Inc. | In situ gel-forming delivery systems, methods and compositions |
| JOP20210266A1 (en) * | 2019-03-29 | 2023-01-30 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| WO2020201138A1 (en) * | 2019-03-29 | 2020-10-08 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| CA3141871A1 (en) * | 2019-05-31 | 2020-12-03 | Qed Therapeutics, Inc. | Methods of treating urinary system cancers |
| WO2021119108A1 (en) * | 2019-12-09 | 2021-06-17 | Cedars-Sinai Medical Center | Use of fgfr inhibitors for treatment of idiopathic short stature |
| BR112022015827A2 (en) * | 2020-02-12 | 2022-10-04 | Janssen Pharmaceutica Nv | FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HIGH RISK INVASIVE NON-MUSCULAR BLADDER CANCER |
| MX2022009904A (en) * | 2020-02-12 | 2022-08-25 | Janssen Pharmaceutica Nv | FGFR TYROSINE KINASE INHIBITORS AND ANTI-PD1 AGENTS FOR THE TREATMENT OF UROTHELIAL CARCINOMA. |
| CA3195543A1 (en) * | 2020-09-17 | 2022-03-24 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating adenoid cystic carcinoma |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200201A1 (en) * | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
-
2018
- 2018-02-02 PT PT187022991T patent/PT3576740T/en unknown
- 2018-02-02 WO PCT/EP2018/052694 patent/WO2018141921A1/en not_active Ceased
- 2018-02-02 MA MA47408A patent/MA47408B1/en unknown
- 2018-02-02 TW TW107103846A patent/TWI798199B/en active
- 2018-02-02 EA EA201991818A patent/EA201991818A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA47408B1 (en) | 2023-08-31 |
| WO2018141921A1 (en) | 2018-08-09 |
| EA201991818A1 (en) | 2020-02-05 |
| PT3576740T (en) | 2023-08-18 |
| TWI798199B (en) | 2023-04-11 |
| TW201839399A (en) | 2018-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3488001A4 (en) | TREATMENT OF CANCER | |
| MA49144A (en) | POLYTHERAPIES FOR THE TREATMENT OF CANCER | |
| IL255261A0 (en) | Cancer treatment methods | |
| MA47501A (en) | CYCLIC DI-NUCLEOTID DERIVATIVE FOR CANCER TREATMENT | |
| MA47408A (en) | CANCER TREATMENT | |
| EP3388004A4 (en) | TREATMENT INSTRUMENT | |
| PL3283527T3 (en) | COMBINED TREATMENT OF CANCER | |
| EP3621592A4 (en) | POLYTHERAPIES FOR CANCER TREATMENT | |
| MA50409A (en) | POLYTHERAPIES FOR THE TREATMENT OF CANCER | |
| EP3432888A4 (en) | TREATMENT OF CANCER WITH TG02 | |
| MA41555A (en) | POLYTHERAPY FOR CANCER TREATMENT | |
| EP3448263A4 (en) | ELECTROTHERAPEUTIC TREATMENT | |
| EP3606531A4 (en) | CANCER TREATMENT METHODS | |
| EP3474854A4 (en) | CANCER TREATMENT COMBINATIONS | |
| MA45429A (en) | POLYTHERAPY FOR CANCER TREATMENT | |
| EP3389645A4 (en) | COMBINATIONS FOR THE TREATMENT OF CANCER | |
| PT3622953T (en) | COMBINED TREATMENT OF CANCER | |
| MA52627A (en) | CANCER TREATMENT | |
| EP3375108A4 (en) | DEWLAN TREATMENT | |
| EP3359255A4 (en) | POLYTHERAPIES FOR THE TREATMENT OF CANCER | |
| MA46361A (en) | TREATMENT OF PROSTATE CANCER | |
| EP3733175A4 (en) | CANCER TREATMENT | |
| IL268463A (en) | Cancer treatment | |
| EP3610026A4 (en) | BLADDER CANCER TREATMENT METHODS | |
| EP3546020C0 (en) | CANCER TREATMENT DEVICE |